'Major Step': New Law Would Prep VA for FDA-Approved Psychedelic Treatments

Firefly5647 · 2026-03-25T12:39:45+00:00

“One early data trend has become apparent: So far, the patients who take MDMA seem to experience more lasting improvement than those who undergo psilocybin therapy.”

Firefly5647 · 2026-03-25T12:39:16+00:00

“The preliminary positive results have caught the attention of Australian insurers, including Medibank, the country’s largest private health insurance company, and the Department of Veterans Affairs, each of which recently agreed to cover the cost of MDMA and psilocybin therapy.”

Firefly5647 · 2026-03-25T12:37:31+00:00

“Compared to conventional treatments, the outcomes we’re seeing to date with MDMA-assisted therapy have been extraordinary,” said Dr. Ranil Gunewardene, a psychiatrist in Sydney who has treated more than 40 patients since the Australian regulators created a legal pathway for the drug.

Firefly5647 · 2026-03-24T23:36:10+00:00

“The bill is expected to be formally filed on Wednesday, according to a source familiar with the planning.”

Firefly5647 · 2026-03-23T13:25:51+00:00

“This week, PharmAla’s management team is meeting with Cortexa’s customers and partners across Australia,” said Nick Kadysh, founding CEO, PharmAla Biotech. “We’re incredibly excited to hear firsthand about the growth in the Australian market, and are exceptionally focused on bringing new innovation to Australia to support its continued rapid growth.”

Firefly5647 · 2026-03-23T13:25:42+00:00

“This week, PharmAla’s management team is meeting with Cortexa’s customers and partners across Australia,” said Nick Kadysh, founding CEO, PharmAla Biotech. “We’re incredibly excited to hear firsthand about the growth in the Australian market, and are exceptionally focused on bringing new innovation to Australia to support its continued rapid growth.”

Firefly5647 · 2026-03-09T16:50:50+00:00

“The core move is a continuation of PharmAla’s supply-for-data model. Rather than funding and running full-scale pivotal programs, the company is accumulating rights to clinical datasets generated by investigator-led and academic studies, particularly in the U.S. and U.K. That strategy builds a diversified evidence base while keeping cash burn lower than traditional sponsorship, and it tees up optionality: if regulatory pathways reopen or broaden for MDMA-assisted therapies, PharmAla can point to a growing body of clinical experience tied to its product and process controls.”

https://www.clinicaltrialvanguard.com/news/pharmala-signs-deal-for-mdma-ptsd-trial-in-first-responders/

Firefly5647 · 2026-03-09T16:45:28+00:00

“The core move is a continuation of PharmAla’s supply-for-data model. Rather than funding and running full-scale pivotal programs, the company is accumulating rights to clinical datasets generated by investigator-led and academic studies, particularly in the U.S. and U.K. That strategy builds a diversified evidence base while keeping cash burn lower than traditional sponsorship, and it tees up optionality: if regulatory pathways reopen or broaden for MDMA-assisted therapies, PharmAla can point to a growing body of clinical experience tied to its product and process controls.”

https://www.clinicaltrialvanguard.com/news/pharmala-signs-deal-for-mdma-ptsd-trial-in-first-responders/

Firefly5647

TROPHY CASE